PRO-NOVELTY: Patient-Reported Outcomes in NOse VEstibule interventionaL radioTherapY (brachytherapy)

L. Tagliaferri, Elisabetta Sciurti, B. Fionda, Antonella Loperfido, V. Lancellotta, E. Placidi, Claudio Parrilla, Maria Concetta La Milia, Enrico Rosa, M. Rigante, M. De Angeli, P. Cornacchione, Jacopo Galli, Francesco Bussu, M. Gambacorta
{"title":"PRO-NOVELTY: Patient-Reported Outcomes in NOse VEstibule interventionaL radioTherapY (brachytherapy)","authors":"L. Tagliaferri, Elisabetta Sciurti, B. Fionda, Antonella Loperfido, V. Lancellotta, E. Placidi, Claudio Parrilla, Maria Concetta La Milia, Enrico Rosa, M. Rigante, M. De Angeli, P. Cornacchione, Jacopo Galli, Francesco Bussu, M. Gambacorta","doi":"10.3390/jcm13164683","DOIUrl":null,"url":null,"abstract":"Background: The aim of this paper is to evaluate the impact on the quality of life of the treatment of nasal vestibule tumors by interventional radiotherapy (IRT-brachytherapy) through a patient reported outcome questionnaire. Methods: We prospectively collected data about patients undergoing IRT according to our institutional schedule of 44 Gy delivered in 14 fractions twice a day. We recorded both acute toxicity data, using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and quality of life data, using the 22-item Sino-Nasal Outcome Test (SNOT-22) at baseline (T0), at 1 month (T1), at 3 months (T3), and at 6 months (T6). Results: We enrolled 10 consecutive patients treated between February 2023 and October 2023. The decrease in terms of SNOT-22 mean value was statistically significant from T0 and T6 with a p-value < 0.001. A noteworthy clinical finding is that quality of life improved regardless of the occurrence of G1-G2 side effects. Conclusions: Using SNOT-22 on patients with nasal vestibule carcinoma treated with IRT has shown an improvement in quality of life that is not strictly dependent on the occurrence of expected G1-G2 side effects.","PeriodicalId":510228,"journal":{"name":"Journal of Clinical Medicine","volume":"64 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/jcm13164683","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The aim of this paper is to evaluate the impact on the quality of life of the treatment of nasal vestibule tumors by interventional radiotherapy (IRT-brachytherapy) through a patient reported outcome questionnaire. Methods: We prospectively collected data about patients undergoing IRT according to our institutional schedule of 44 Gy delivered in 14 fractions twice a day. We recorded both acute toxicity data, using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and quality of life data, using the 22-item Sino-Nasal Outcome Test (SNOT-22) at baseline (T0), at 1 month (T1), at 3 months (T3), and at 6 months (T6). Results: We enrolled 10 consecutive patients treated between February 2023 and October 2023. The decrease in terms of SNOT-22 mean value was statistically significant from T0 and T6 with a p-value < 0.001. A noteworthy clinical finding is that quality of life improved regardless of the occurrence of G1-G2 side effects. Conclusions: Using SNOT-22 on patients with nasal vestibule carcinoma treated with IRT has shown an improvement in quality of life that is not strictly dependent on the occurrence of expected G1-G2 side effects.
PRO-NOVELTY:鼻气管介入放射治疗(近距离放射治疗)患者报告结果
背景:本文旨在通过患者报告结果问卷,评估介入放射治疗(IRT-近距离放射治疗)对鼻前庭肿瘤患者生活质量的影响。研究方法我们前瞻性地收集了接受介入放射治疗的患者的数据,该治疗是按照本院的计划进行的,每天两次,每次 14 分次,每次 44 Gy。我们记录了基线(T0)、1 个月(T1)、3 个月(T3)和 6 个月(T6)时的急性毒性数据(采用通用不良事件术语标准 (CTCAE) 5.0 版)和生活质量数据(采用 22 项中鼻结局测试 (SNOT-22))。结果:我们在 2023 年 2 月至 2023 年 10 月期间连续收治了 10 名患者。从 T0 到 T6,SNOT-22 平均值的下降具有统计学意义,P 值小于 0.001。值得注意的临床发现是,无论出现 G1-G2 副作用与否,患者的生活质量都有所改善。结论对接受 IRT 治疗的鼻前庭癌患者使用 SNOT-22 结果显示,生活质量的改善并不完全取决于 G1-G2 副作用的发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信